DOCSLIB.ORG

Labelers Numeric

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Labelers Numeric MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 05/13/2021 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:39:26 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 07/01/2021 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00186 ASTRAZENECA PHARMACEUTICALS LP 00003 E.R. SQUIBB & SONS, LLC. 00187 BAUSCH HEALTH US, LLC. 00004 HOFFMANN-LA ROCHE 00206 WYETH PHARMACEUTICALS LLC, 00006 MERCK & CO., INC. 00224 KONSYL PHARMACEUTICALS, INC. 00007 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00008 WYETH PHARMACEUTICALS LLC, 00228 ACTAVIS PHARMA, INC. 00009 PHARMACIA AND UPJOHN COMPANY LLC 00245 UPSHER-SMITH LABORATORIES, INC. 00013 PFIZER LABORATORIES DIV PFIZER INC 00254 PAR PHARMACEUTICAL INC. 00015 MEAD JOHNSON AND COMPANY 00259 MERZ PHARMACEUTICALS 00023 ALLERGAN INC 00264 B. BRAUN MEDICAL INC. 00024 SANOFI-AVENTIS, US LLC 00281 SAVAGE LABORATORIES 00025 PFIZER LABORATORIES DIV PFIZER INC 00299 GALDERMA LABORATORIES, L.P. 00026 BAYER HEALTHCARE LLC 00310 ASTRAZENECA PHARMACEUTICALS LP 00032 ABBVIE INC. 00338 BAXTER HEALTHCARE CORPORATION 00037 MEDA PHARMACEUTICALS, INC. 00378 MYLAN PHARMACEUTICALS, INC. 00039 SANOFI-AVENTIS, US LLC 00406 SPEC GX, LLC 00046 WYETH PHARMACEUTICALS INC. 00407 GE HEALTHCARE, INC. 00049 ROERIG 00409 HOSPIRA, INC. 00051 ABBVIE INC 00430 WARNER CHILCOTT (US) LLC 00052 ORGANON USA INC. 00456 FOREST LABORATORIES, INC. 00053 CSL BEHRING L.L.C. 00469 ASTELLAS PHARMA US, INC. 00054 HIKMA PHARMACEUTICAL USA, INC. 00472 ACTAVIS PHARMA, INC. 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00485 EDWARDS PHARMACEUTICALS, INC. 00065 ALCON LABORATORIES, INC. 00486 BEACH PHARMACEUTICALS 00068 AVENTIS PHARMACEUTICALS 00487 NEPHRON PHARMACEUTICALS CORPORATION 00069 PFIZER LABORATORIES DIV PFIZER INC 00517 AMERICAN REGENT, INC. 00071 PARKE-DAVIS DIV OF PFIZER 00527 LANNETT COMPANY, INC. 00074 ABBVIE INC 00536 RUGBY LABORATORIES 00075 AVENTIS PHARMACEUTICALS, INC. 00548 AMPHASTAR PHARMACEUTICALS, INC. 00078 NOVARTIS 00555 TEVA PHARMACEUTICALS USA, INC 00085 SCHERING CORPORATION 00562 KEDRION MELVILLE, INC. 00087 BRISTOL-MYERS SQUIBB COMPANY 00574 PADDOCK LABORATORIES, LLC. 00088 AVENTIS PHARMACEUTICALS 00575 TEVA PHARMACEUTICALS USA, INC 00093 TEVA PHARMACEUTICALS USA, INC. 00591 ACTAVIS PHARMA, INC. 00095 BAUSCH HEALTH US, LLC 00597 BOEHRINGER INGELHEIM PHARMACEUTICALS 00096 PERSON & COVEY, INC. 00603 PAR PHARMACEUTICAL 00113 L. PERRIGO COMPANY 00641 HIKMA PHARMACEUTICAL USA, INC. 00115 IMPAX GENERICS 00642 EXELTIS USA, INC. 00116 XTTRIUM LABORATORIES, INC. 00682 MARNEL PHARMACEUTICALS, LLC 00121 PHARMACEUTICAL ASSOCIATES, INC. 00703 TEVA PARENTERAL MEDICINES INC 00131 UCB, INC. 00713 COSETTE PHARMACEUTICALS, INC. 00132 C B FLEET COMPANY INC 00777 DISTA PRODUCTS COMPANY 00143 HIKMA PHARMACEUTICAL USA, INC. 00781 SANDOZ 00145 STIEFEL LABORATORIES, INC, 00813 PHARMICS INC. 00168 E FOUGERA AND CO. 00832 UPSHER-SMITH LABORATORIES, LLC. 00169 NOVO NORDISK, INC. 00884 PEDINOL PHARMACAL INC 00172 TEVA PHARMACEUTICALS USA, INC 00904 MAJOR PHARMACEUTICALS 00173 GLAXOSMITHKLINE 00941 BAXTER HEALTHCARE CORPORATION 00178 MISSION PHARMACAL COMPANY 00944 BAXALTA US INC. 00185 EON LABS, INC. 00955 SANOFI-SYNTHELABO INC. MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 05/13/2021 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:39:26 REPORT ID 2794D051 PAGE: 02 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 07/01/2021 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00990 ICU MEDICAL INC. 18657 HALOZYME THERAPEUTICS, INC. 00998 ALCON LABORATORIES, INC. 18860 JAZZ PHARMACEUTICALS, INC 05551 AMGEN INC 20536 TALON THERAPEUTICS, INC 08221 ARBOR PHARM IRELAND LIMITED 21724 INDEPENDENCE PHARMACEUTICALS, LLC 10019 BAXTER HEALTHCARE CORPORATION 21922 ENCUBE ETHICALS PVT. LTD. 10094 AQUESTIVE THERAPEUTICS 23155 HERITAGE PHARMACEUTICALS, INC. 10122 CHIESI USA, INC. 23359 CENTURION LABS, LLC 10144 ACORDA THERAPEUTICS, INC. 23594 ZYLERA PHARMACEUTICALS, LLC 10147 PATRIOT PHARMACEUTICALS, LLC. 23635 SPEC GX, LLC. 10148 COTHERIX, INC. 24201 LEUCADIA PHARMACEUTICALS 10337 DOAK DERMATOLOGICS 24208 BAUSCH & LOMB INC. 10370 PAR PHARMACEUTICALS, INC. 24338 ARBOR PHARMACEUTICALS, LLC. 10454 SOLSTICE NEUROSCIENCES, LLC. 24385 AMERISOURCE BERGEN 10542 HILLESTAD PHARMACEUTICALS USA 24478 NEXTWAVE PHARMACEUTICALS, INC. 10572 AFFORDABLE PHARMACEUTICALS, LLC 24492 PARI RESPIRATORY EQUIPMENT, INC. 10599 INTERSECT ENT, INC. 24510 COLLEGIUM PHARMACEUTICAL, INC. 10631 SUN PHARMACEUTICALS INDUSTRIES, INC. 24658 PURACAP LAB. DBA BLU PHARMACEUTICALS 10702 KVK-TECH, INC. 24689 APNAR PHARMA LP 10885 GALEN US INCORPORATED 24979 TWI PHARMACEUTICALS, INC. 10922 INTENDIS, INC. 25010 BAUSCH HEALTH US, LLC 11042 MIDDLEBROOK PHARMACEUTICALS, INC. 25021 SAGENT PHARMACEUTICALS, INC. 11527 SHEFFIELD PHARMACEUTICALS 25208 MEDICURE INTERNATIONAL, INC. 11534 SUNRISE PHARMACEUTICAL, INC. 25682 ALEXION PHARMACEUTICALS 11980 ALLERGAN INC 27241 AJANTA PHARMA LIMITED 11994 LANTHEUS MEDICAL IMAGING, INC. 27437 LUPIN PHARMACEUTICALS, INC. 12496 INDIVOR INC. 27505 US WORLDMEDS, LLC 12830 R.A. MCNEIL COMPANY 27808 TRIS PHARMA, INC. 13107 AUROBINDO PHARMA USA, INC. 28595 ALLEGIS PHARMACEUTICALS LLC 13517 E5 PHARMA, LLC 29033 NOSTRUM LABORATORIES 13533 GRIFOLS USA, LLC 29300 UNICHEM PHARMACEUTICALS, INC. 13548 BAUSCH HEALTH US, LLC 29978 CAPITAL PHARMACEUTICAL, LLC 13668 TORRENT PHARMACEUTICALS LIMITED 30237 DENDREON PHARMACEUTICALS LLC 13811 TRIGEN LABORATORIES, LLC 30698 VALIDUS PHARMACEUTICALS, INC. 13845 PARSOLEX GMP CENTER, INC. 31722 CAMBER PHARMACEUTICALS, INC. 13913 ASSERTIO THERAPEUTICS, INC. 33342 MACLEODS PHARMACEUTICALS LIMITED 13925 SETON PHARMACEUTICALS, LLC 33573 STESSO PHARMACEUTICALS 14539 HERITAGE PHARMACEUTICALS, INC. 35573 BUREL PHARMACEUTICALS 14789 NEXUS PHARMACEUTICALS, INC. 36000 BAXTER HEALTHCARE CORPORATION 15054 IPSEN BIOPHARMACEUTICALS 36800 TOPCO ASSOCIATES LLC 15370 CARWIN PHARMACEUTICAL ASSOCIATES, LLC. 37205 CARDINAL HEALTH 15584 GILEAD SCIENCES, LLC. 39328 PATRIN PHARMA, INC. 16252 ACTAVIS PHARMA, INC. 39822 X-GEN PHARMACEUTICALS 16571 RISING PHARMACEUTICALS, INC 40076 PRESTIUM PHARMA, INC. 16714 NORTHSTAR RX LLC 40085 RENAISSANCE PHARMA, INC. 16729 ACCORD HEALTHCARE INC. 41616 SUN PHARMA GLOBAL, INC. 16781 BAUSCH HEALTH US, LLC 42023 PAR PHARMACEUTICAL, INC. 17314 JANSSEN PHARMACEUTICALS, INC 42043 ORCHIDPHARMA, INC. 17433 ENEMEEZ, INC. DBA SUMMIT PHARMACEUTICAL 42192 ACELLA PHARMACEUTICALS, LLC 17478 AKORN INC 42195 XSPIRE PHARMA LLC 17772 SUPERNUS PHARMACEUTICALS, INC. 42211 IROKO PHARMACEUTICALS LLC MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 05/13/2021 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:39:26 REPORT ID 2794D051 PAGE: 03 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 07/01/2021 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 42227 VIROPHARMA BIOLOGICS, INC. 47918 MANNKIND CORPORATION 42292 MYLAN INSTITUTIONAL INC. 48102 FERA PHARMACEUTICALS, LLC 42358 SENTYNL THERAPEUTICS, INC. 48818 ALLOS THERAPEUTICS INC. 42367 EAGLE PHARMACEUTICALS, INC. 49230 FRESENIUS MEDICAL CARE NORTH AMERICA 42385 LAURUS LABS PRIVATE LIMITED 49281 SANOFI PASTEUR INC 42388 EXELIXIS, INC. 49348 STRATEGIC SOURCING SERVICES LLC 42457 EMMAUS MEDICAL, INC. 49401 GLAXOSMITHKLINE LLC 42494 CAMERON PHARMACEUTICALS, LLC. 49411 CLOVER PHARMACEUTICALS CORPORATION 42543 VENSUN PHARMACEUTICALS, INC. 49483 TIME CAP LABORATORIES, INC. 42571 MICRO LABS LIMITED 49502 MYLAN SPECIALTY L.P. 42658 HISUN PHARMACEUTICALS USA, INC. 49687 ACTAVIS KADIAN LLC 42667 ACERUS PHARMACEUTICALS CORPORATION 49702 VIIV HEALTHCARE COMPANY 42702 PARAGON BIOTECK, INC. 49708 SUN PHARMACEUTICALS INDUSTRIES, INC. 42747 KYOWA KIRIN, INC, 49730 HERCON PHARMACEUTICALS, LLC 42794 SIGMAPHARM LABORATORIES, LLC 49884 PAR PHARMACEUTICAL 42799 EDENBRIDGE PHARMACEUTICALS LLC 49909 EDGEMONT PHARMACEUTICALS, LLC 42806 EPIC PHARMA LLC 49938 JACOBUS PHARMACEUTICALS CO INC. 42847 CURRAX PHARMACEUTICALS, LLC. 50102 AFAXYS PHARMA, INC. 42858 RHODES PHARMACEUTICALS L.P. 50111 TEVA PHARMACEUTICALS USA, INC 42865 APTALIS PHARMA US, INC 50222 LEO PHARMA INC. 42998 MARATHON PHARMAEUTICALS, LLC 50228 SCIEGEN PHARMACEUTICALS, INC. 43066 BAXTER HEALTHCARE CORPORATION 50242 GENENTECH, INC. 43068 VANDA PHARMACEUTICALS, INC. 50261 THERAPEUTICSMD 43199 COUNTY LINE PHARMACEUTICALS, LLC 50268 AVPAK 43376 ZOGENIX, INC. 50383 HI-TECH PHARMACAL CO. INC. 43386 LUPIN PHARMACEUTICALS, INC. 50419 BAYER HEALTHCARE PHARMACEUTICALS, INC 43393 GENBIOPRO, INC. 50458 JANSSEN PHARMACEUTICALS, INC 43485 APRECIA PHARMACEUTICALS, LLC 50474 UCB, INC. 43538 MEDIMETRIKS PHARMACEUTICALS, INC. 50742 INGENUS PHARMACEUTICALS, LLC 43547 SOLCO HEALTHCARE USA, LLC 50844 LNK INTERNATIONAL, INC. 43598 DR. REDDY'S LABORATORIES, INC. 50881 INCYTE CORPORATION 43975 ANI PHARMACEUTICALS, INC. 50967 WOMENS CHOICE PHARMACEUTICALS 44087 EMD SERONO, INC. 50991 POLY PHARMACEUTICALS, INC. 44183 CURRAX PHARMACEUTICALS, LLC. 51021 SIRCLE LABORATORIES, LLC 44206 CSL BEHRING AG 51079 MYLAN INSTITUTIONAL, INC 44523 BIOCOMP PHARMA, INC. 51144 SEAGAN INC. 44567 WG CRITICAL CARE, LLC 51167 VERTEX PHARMACEUTICALS, INC. 45043 MANCHESTER PHARMACEUTICALS CORPORATION 51224 TAGI PHARMA, INC 45802 PERRIGO NEW YORK INC. 51248 ASTELLAS PHARMA US, INC. 45945 MALLINCKRODT, LLC 51267 NALPROPION PHARMACEUTICALS 45963 ACTAVIS PHARMA, INC. 51285 TEVA WOMENS HEALTH INC 46017 MYLAN CONSUMER HEALTHCARE, INC. 51293 ECI PHARMACEUTICALS LLC 46122
Load more

Recommended publications
  • Infectious Diseases
    2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases.
    [Show full text]
  • Corporate Governance Report 2014
    CORPORATE GOVERNANCE REPORT Sobi’s Corporate Governance Swedish Orphan Biovitrum AB (publ) “Sobi” is a Swedish adopts the annual report and interim reports, and pro- neration programmes. This includes an overview, and pro- public limited liability company with its registered office poses dividends, if any, to the AGM. posals for remuneration to senior executives and for in Stockholm, Sweden. Sobi is listed on Nasdaq Stock- The Board’s work is based on its working procedures, long-term incentive programmes, pension plans and other holm. In addition to the rules stipulated by law or other CEO instructions and the principles for the division of duties issues relating to remuneration to the company’s employees. statutes, Sobi applies the Swedish Corporate Governance between the CEO, the Chairman of the Board, Board mem- Code complete. This report pertains to the 2014 financial bers and various committees established by the Board. The 6. Scientific Committee year and is a part of Sobi’s Directors’ Report and has been Board’s working procedures and instructions for the CEO The Scientific Committee’s tasks include advising on scien- reviewed by the company’s auditors. are revised and updated once a year. The Chairman of the tific matters, evaluating the Company’s research strategies, Board leads the Board’s work, monitors the company’s per- and monitoring and reporting to the Board on scientific 1. Annual General Meeting formance, ensures that important issues are addressed as trends and new fields of research. Sobi’s highest decision-making body is the Annual General needed and that all important decisions are preceded by Meeting (AGM) at which all shareholders have the right to active and constructive discussion.
    [Show full text]
  • Print Layout 1
    TECHNICAL PROGRAM Monday, March 19 5:00 – 8:00 pm Welcome Reception Tuesday, March 20 8:00 – 10:00 Session 1: Setting the Conference Context and Drivers Chair: Geoff Slaff (Amgen) Roger Perlmutter (Amgen) Conquering the Innovation Deficit in Drug Discovery Helen Winkle (CDER, FDA) Regulatory Modernization 10:00 – 10:30 Break Vendor and poster review 10:30 – 12:30 Session 2: Rapid Cell Line Development and Improved Expression System Development Chairs: Timothy Charlebois (Wyeth) and John Joly (Genentech) Amy Shen (Genentech) Stable Antibody Production Cell-Line Development with an Improved Selection Process and Accelerated Timeline Mark Leonard (Wyeth) High-Performing Cell-Line Development within a Rapid and Integrated Platform Process Control Pranhitha Reddy (Amgen) Applying Quality-by-Design to Cell Line Development Lin Zhang (Pfizer) Development of a Fully-Integrated Automated System for High-Throughput Screening and Selection of Single Cells Expressing Monoclonal Antibodies 12:30 – 2:00 Lunch Vendor and poster review 2:00 – 4:30 Session 3: High-Throughput Bulk Process Development Chairs: Brian Kelley (Wyeth) and Jorg Thommes (Biogen Idec) Colette Ranucci (Merck) Development of a Multi-Well Plate System for High-Throughput Process Development Min Zhang (SAFC Biosciences) CHO Media Library – an Efficient Platform for Rapid Development and Optimization of Cell Culture Media Supporting High Production of Pharmaceutical Proteins in Chinese Hamster Ovary Cells Nigel Titchener-Hooker The Use of Ultra-Scale-Down Approaches to Enable Rapid Investigation
    [Show full text]
  • March 31, 2021
    Units Cost Market Value US Equity Index Fund US Equities 95.82% Domestic Common Stocks 10X GENOMICS INC 126 10,868 24,673 1LIFE HEALTHCARE INC 145 6,151 4,794 2U INC 101 5,298 4,209 3D SYSTEMS CORP 230 5,461 9,193 3M CO 1,076 182,991 213,726 8X8 INC 156 2,204 4,331 A O SMITH CORP 401 17,703 28,896 A10 NETWORKS INC 58 350 653 AAON INC 82 3,107 5,132 AARON'S CO INC/THE 43 636 1,376 ABBOTT LABORATORIES 3,285 156,764 380,830 ABBVIE INC 3,463 250,453 390,072 ABERCROMBIE & FITCH CO 88 2,520 4,086 ABIOMED INC 81 6,829 25,281 ABM INDUSTRIES INC 90 2,579 3,992 ACACIA RESEARCH CORP 105 1,779 710 ACADIA HEALTHCARE CO INC 158 8,583 9,915 ACADIA PHARMACEUTICALS INC 194 6,132 4,732 ACADIA REALTY TRUST 47 1,418 1,032 ACCELERATE DIAGNOSTICS INC 80 1,788 645 ACCELERON PHARMA INC 70 2,571 8,784 ACCO BRANDS CORP 187 1,685 1,614 ACCURAY INC 64 483 289 ACI WORLDWIDE INC 166 3,338 6,165 ACTIVISION BLIZZARD INC 1,394 52,457 133,043 ACUITY BRANDS INC 77 13,124 14,401 ACUSHNET HOLDINGS CORP 130 2,487 6,422 ADAPTHEALTH CORP 394 14,628 10,800 ADAPTIVE BIOTECHNOLOGIES CORP 245 11,342 10,011 ADOBE INC 891 82,407 521,805 ADT INC 117 716 1,262 ADTALEM GLOBAL EDUCATION INC 99 4,475 3,528 ADTRAN INC 102 2,202 2,106 ADVANCE AUTO PARTS INC 36 6,442 7,385 ADVANCED DRAINAGE SYSTEMS INC 116 3,153 13,522 ADVANCED ENERGY INDUSTRIES INC 64 1,704 7,213 ADVANCED MICRO DEVICES INC 2,228 43,435 209,276 ADVERUM BIOTECHNOLOGIES INC 439 8,321 1,537 AECOM 283 12,113 17,920 AERIE PHARMACEUTICALS INC 78 2,709 1,249 AERSALE CORP 2,551 30,599 31,785 AES CORP/THE 1,294 17,534 33,735 AFFILIATED
    [Show full text]
  • 2020 Annual Report Products
    Products 2020 Annual Report From the CEO Dear Fellow Shareholders, Perrigo’s transformation to a pure-play Consumer Self-Care Company has come a long way LQMXVWWZRVKRUW\HDUV:HKDYHUHVWRUHGVXVWDLQDEOHWRSOLQHJURZWKGHOLYHUHGRQRXU¿QDQFLDO SURPLVHVUHFRQ¿JXUHGRXUSRUWIROLRRIEXVLQHVVHVXSGDWHGWKH,7LQIUDVWUXFWXUHDQGSURFHVVHV of the Company, expanded capacity, upgraded leadership talent, installed business intelligence capabilities, built a new product pipeline of over $500 million and re-instilled a sense of pride and energy among our 11,000 team members. Making this even more remarkable, is that we kept the WUDQVIRUPDWLRQRQWUDFNLQWKHIDFHRIWKHJOREDO&29,'SDQGHPLF,KRSH\RXDUHDVSURXGRI3HUULJR¶VJOREDOWHDP DV,DPIRUKRZWKH\ZRUNHGWRNHHSHDFKRWKHUVDIHNHSWRXUHVVHQWLDOSURGXFWVÀRZLQJDQGNHSWRXUWUDQVIRUPDWLRQ to a consumer self-care company on track through all of the personal and professional uncertainty that came their way LQ7KH\DUHKHURHV As a result of their efforts, Perrigo delivered strong net sales growth for the second year in a row in 2020 and World-wide Consumer sales reached a new record high. Equally important, the team stabilized adjusted operating income after a few years of decline even as we invested over $50 million in our business and overcame $35 million RIXQSODQQHGKHDGZLQGVGXHSULPDULO\WR&29,'UHODWHGVDIHW\FRVWVDQGEXVLQHVVLPSDFWIURPWKHZHDNFROG FRXJKDQGÀXVHDVRQUHODWHGWR&29,'¶VLPSDFWRQSXEOLFOLIH$OOLQDOOZHKDGDYHU\VWURQJ\HDU Our transformation efforts reached an essential milestone after the year closed when we announced the sale of RXU3UHVFULSWLRQ3KDUPDFHXWLFDOVEXVLQHVVWR$OWDULV&DSLWDO3DUWQHUV//&7KHWUDQVDFWLRQUHLQIRUFHVRXUDELOLW\
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • Market Cap Close ADV
    Market Cap Close ADV 1598 67th Pctl $745,214,477.91 $23.96 225,966.94 801 33rd Pctl $199,581,478.89 $10.09 53,054.83 2399 Listing_ Revised Ticker_Symbol Security_Name Exchange Effective_Date Mkt Cap Close ADV Stratum Stratum AAC AAC Holdings, Inc. N 20160906 M M M M-M-M M-M-M Altisource Asset Management AAMC Corp A 20160906 L M L L-M-L L-M-L AAN Aarons Inc N 20160906 H H H H-H-H H-H-H AAV Advantage Oil & Gas Ltd N 20160906 H L M H-L-M H-M-M AB Alliance Bernstein Holding L P N 20160906 H M M H-M-M H-M-M ABG Asbury Automotive Group Inc N 20160906 H H H H-H-H H-H-H ABM ABM Industries Inc. N 20160906 H H H H-H-H H-H-H AC Associated Capital Group, Inc. N 20160906 H H L H-H-L H-H-L ACCO ACCO Brand Corp. N 20160906 H L H H-L-H H-L-H ACU Acme United A 20160906 L M L L-M-L L-M-L ACY AeroCentury Corp A 20160906 L L L L-L-L L-L-L ADK Adcare Health System A 20160906 L L L L-L-L L-L-L ADPT Adeptus Health Inc. N 20160906 M H H M-H-H M-H-H AE Adams Res Energy Inc A 20160906 L H L L-H-L L-H-L American Equity Inv Life Hldg AEL Co N 20160906 H M H H-M-H H-M-H AF Astoria Financial Corporation N 20160906 H M H H-M-H H-M-H AGM Fed Agricul Mtg Clc Non Voting N 20160906 M H M M-H-M M-H-M AGM A Fed Agricultural Mtg Cla Voting N 20160906 L H L L-H-L L-H-L AGRO Adecoagro S A N 20160906 H L H H-L-H H-L-H AGX Argan Inc N 20160906 M H M M-H-M M-H-M AHC A H Belo Corp N 20160906 L L L L-L-L L-L-L ASPEN Insurance Holding AHL Limited N 20160906 H H H H-H-H H-H-H AHS AMN Healthcare Services Inc.
    [Show full text]
  • Ipo Analysis
    IPO ANALYSIS Snap Research on potential upcoming IPOs from Hamilton Lane Bitcoin Investment Trust selected candidate companies. Visterra Braeburn Pharmaceuticals December, 2016 VentureDeal Snap Files S-1 Registration For $3 Billion IPO Quick Take Camera company Snap Inc. (Pending:SNAP) has filed its initial S-1 registration for a $3 billion IPO at an undisclosed valuation. Snap views the camera as the primary use of the mobile device and seeks to monetize its user base primarily through advertising. The company has a short history of rapidly growing revenues, which exceeded $400 million in 2016. Company Venice-based Snap was founded in 2012 by current CEO Evan Spiegel and current CTO Robert Murphy to initially provide users with a smartphone app that enabled them to post pictures that were automatically deleted after a brief time period. The company has since expanded its scope to include chat, video, media that does not become automatically deleted, and a camera integrated into sunglasses. Below is a brief company video on its recently introduced Spectacles product: (Source: Snap YouTube) Snap has raised in excess of $2.6 billion in several private financing rounds from numerous investors including top tier venture capital firms, corporate investors, private equity firms and government-owned investment enterprises. The company claims that 158 million people use its flagship Snapchat each day, creating over 2.5 billion 'Snaps'. Market and Competition Snap operates a largely advertising-driven business model, although it does sell its Spectacles product for $129 each. It seeks to provide advertisers with access to its user base, which has typically centered around a younger demographic, between the ages of 14-30.
    [Show full text]
  • The Year of Investment, Innovation and Implementation
    2017 the year of investment, innovation and implementation 2017 annual report healthcare businesswomen’s association table of contents LETTER FROM CHAIR 1 INVESTMENT 2017 BY THE NUMBERS 2 MEMBERSHIP 2 CHAPTER BREAKDOWN 2 40 YEARS OF MILESTONES 2 MEMBER/VOLUNTEER SURVEY RESULTS 3 FINANCIALS 4 INNOVATION AND IMPLEMENTATION 2017 FLAGSHIP EVENTS 7 WOMAN OF THE YEAR 8 LUMINARIES 10 RISING STARS 11 ANNUAL CONFERENCE 13 ACE AWARDS 14 THE GENDER PARITY COLLABORATIVE CLICK HERE HBA “NOW” THE NEW OPERATING MODEL CLICK HERE IN APPRECIATION—WE COULDN’T DO IT WITHOUT YOU 2017 CORPORATE PARTNERS 15 2017 SPONSORS 16 2017 MEDIA PARTNERS 17 HBA ADVISORY BOARD 18 HBA BOARD OF DIRECTORS 19 LETTER FROM CEO LAURIE COOKE 20 HBA 2017 II annual report letter from the chair In my long career as a healthcare executive, I have seen firsthand the benefits of diversity in leadership time and again. From gender to ethnicity to age and other factors, the best engagement and the most powerful results always arise when there is a diversity of perspectives in the room. This is why I joined the HBA board. This year marks the 40th anniversary of the organization’s founding. And though I am a relatively new member, I quickly became a believer in the HBA’s rich history and deep commitment to both the advancement of women individually, and to the achievement of gender parity in healthcare overall. This is also why I am proud of the HBA’s aggressive—but achievable—strategic plan to move the needle on gender parity through partnership by 2020.
    [Show full text]
  • Biocentury 8.15.16
    WEEK OF AUGUST 15, 2016 6 PRODUCT DEVELOPMENT: NO ANTIGEN LEFT BEHIND Amgen has added to its immuno-oncology arsenal with its deal for Advaxis’ pan- epitope neoantigen vaccine platform. SERVING RETURNS 9 EMERGING COMPANY PROFILE: RESTRAINING TRANSLATION BY STEVE EDELSON, SENIOR EDITOR Bantam is developing small molecule eIF4E inhibitors to treat a range of cancers, China’s Ally Bridge Group hit the investment world’s starting with B cell malignancies. radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with REGULATION: the listing of WuXi’s biologics unit in Hong Kong this 10 year, the question is what will be its next moves to ADAPTING FOR THE REAL WORLD generate outsized returns for its investors. EMA says better strategies for real-world evidence and more patient and payer involvement are necessary Ally Bridge, which has a about $1.5 billion under next steps for its adaptive pathway initiative. management across three funds and an international base of LPs, thinks its returns and continued visibility will come from a handful of public and private portfolio companies with transformative data events, the first of EBB & FLOW: 13 which should come this half. LION’S SHARE OF THE WORK Aslan’s validating event. Plus: Cutting a check The firm also says it is working on new private equity to Cleave; and Ironwood’s operating leverage. deals that will rival WuXi in terms of size and impact. Ally Bridge is keeping its private equity plans under wraps, and does not disclose names of investments in its Asia hedge fund.
    [Show full text]
  • Companies in Attendance
    COMPANIES IN ATTENDANCE Abbott Diabetes Care Archbow Consulting LLC Business One Technologies Abbott Laboratories ARKRAY USA BusinessOneTech AbbVie Armory Hill Advocates, LLC CastiaRX ACADIA Artia Solutions Catalyst Acaria Health Asembia Celgene Accredo Assertio Therapeutics Celltrion Acer Therapeutics AssistRx Center for Creative Leadership Acorda Therapeutics Astellas Pharma US Inc. Cigna Actelion AstraZeneca Cigna Specialty Pharmacy AdhereTech Athenex Oncology Circassia Advantage Point Solutions Avanir Coeus Consulting Group Aerie Pharmaceuticals Avella Coherus Biosciences AGIOS AveXis Collaborative Associates LLC Aimmune Theraputics Bank of America Collegium Akcea Therapeutics Bausch Health Corsica Life Sciences Akebia Therapeutics Bayer U.S. CoverMyMeds Alder BioPharmaceuticals Becton Dickinson Creehan & Company, Inc., an Inovalon Company Alexion Biofrontera CSL Behring Alkermes Biogen Curant Health Allergan Biohaven CVS Health Almirall BioMarin D2 Consulting Alnylam BioMatrix Specialty Pharmacy Daiichi Sankyo Amarin BioPlus Specialty Pharmacy DBV Technologies Amber Pharmacy Bioventus Deloitte Consulting LLP AmerisourceBergen Blue Cross Blue Shield Association Dendreon Amgen Blue Fin Group Dermira Amicus Therapeutics bluebird bio Dexcom Amneal Boehringer Ingelheim Diplomat Pharmacy Anthem Boston Biomedical Dova Applied Policy Bowler and Company Decision Resources Group Aquestive Therapeutics Braeburn Eisai Arbor Pharmaceuticals Bristol-Myers Squibb 1 electroCore Indivior Merz Pharmaceuticals EMD Serono Inside Rx Milliman Encore Dermatology,
    [Show full text]
  • Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc
    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Gathering Momentum Company Overview Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant’s primary focus is principally in the areas of dermatology and neurology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in dermatology and neurology. Valeant plans to strategically expand its pipeline by adding new compounds or products through product or company acquisitions and will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Valeant’s strategic markets are primarily in the United States, Canada, Central and Eastern Europe, Latin America, Australia and South East Asia. Headquartered in Montreal, Quebec, Valeant has approximately 7,000 employees worldwide. FORWARD-LOOKING Statements In addition to current and historical information, this Annual Report contains forward-looking statements, including, without limitation, statements regarding our strategy, expected future revenue, the prospects for approval of product candidates and the timing of regulatory approvals, and the growth and future development of the company, its business units and its products. Words such as “expects,” “anticipates,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” or similar language identify forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties. Our actual results may differ materially from those contemplated by the forward-looking statements.
    [Show full text]